News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


"Sci-fi" cancer therapy fights brain tumors, study finds

Al's Comment:

 This is the final results of the Optune trial.  Survival rates were 43 percent versus 31 percent at two years; 26 percent versus 16 percent at three years, and 13 percent versus 5 percent at five years. These results are impressive.  The survival advantage has improved since the last report as there are now more 5 year survivors.   All subgroups of patients had a benefit - methylated or unmethylated, young or old, gross total resection and biopsy only.  They also clarified their position of letting every patient who wants to use it get it regardless of ability to pay.

Posted on: 04/03/2017

"Sci-fi" cancer therapy fights brain tumors, study finds


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557